take pleasure in Capxib vsample

triggered Capxib annoying
 
Photo :Capxib

and mock Capxib Generic Name: celecoxib, menthol, capsaicin Dosage Form: kit Print this page Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here. CELECOXIB CAPSULES Indications and Usage for Capxib Carefully consider the potential benefits and risks of celecoxib and other treatment options before deciding to use celecoxib capsules. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals Capxib Dosage and Administration Use lowest effective dose for the shortest duration consistent with treatment goals for the individual patient. These doses can be given without regard to timing of meals. DOSAGE FORMS AND STRENGTHS Capsules: 50 mg, 100 mg and 200 mg CONTRAINDICATIONS Celecoxib capsules are contraindicated: In patients with known hypersensitivity to celecoxib, aspirin, or other NSAIDs. In patients who have demonstrated allergic-type reactions to sulfonamides. In patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. Severe anaphylactoid reactions to NSAIDs, some of them fatal, have been reported in such patients. For the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery WARNINGS AND PRECAUTIONS Adverse Reactions Of the celecoxib-treated patients in the pre-marketing controlled clinical trials, approximately 4,250 were patients with OA, approximately 2,100 were patients with RA, and approximately 1,050 were patients with post-surgical pain. More than 8,500 patients received a total daily dose of celecoxib of 200 mg (100 mg twice daily or 200 mg once daily) or more, including more than 400 treated at 800 mg (400 mg twice daily). Approximately 3,900 patients received celecoxib at these doses for 6 months or more; approximately 2,300 of these have received it for 1 year or more and 124 of these have received it for 2 years or more. Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The adverse reaction information from clinical trials does, however, provide a basis for identifying the adverse events that appear to be related to drug use and for approximating rates. Drug Interactions General: Celecoxib metabolism is predominantly mediated via cytochrome P450 (CYP) 2C9 in the liver. Co-administration of celecoxib with drugs that are known to inhibit CYP2C9 should be done with caution. Significant interactions may occur when celecoxib is administered together with drugs that inhibit CYP2C9. In vitro studies indicate that celecoxib, although not a substrate, is an inhibitor of CYP2D6. Therefore, there is a potential for an in vivo drug interaction with drugs that are metabolized by CYP2D6. USE IN SPECIFIC POPULATIONS Overdosage No overdoses of celecoxib were reported during clinical trials. Doses up to 2400 mg/day for up to 10 days in 12 patients did not result in serious toxicity. Symptoms following acute NSAID overdoses are usually limited to lethargy, drowsiness, nausea, vomiting, and epigastric pain, which are generally reversible with supportive care. Gastrointestinal bleeding can occur. Hypertension, acute renal failure, respiratory depression and coma may occur, but are rare. Anaphylactoid reactions have been reported with therapeutic ingestion of NSAIDs, and may occur following an overdose. Patients should be managed by symptomatic and supportive care following an NSAID overdose. There are no specific antidotes. No information is available regarding the removal of celecoxib by hemodialysis, but based on its high degree of plasma protein binding (>97%) dialysis is unlikely to be useful in overdose. Emesis and/or activated charcoal (60 to 100 g in adults, 1 to 2 g/kg in children) and/or osmotic cathartic may be indicated in patients seen within 4 hours of ingestion with symptoms or following a large overdose. Forced diuresis, alkalinization of urine, hemodialysis, or hemoperfusion may not be useful due to high protein binding. Capxib Description Celecoxib is chemically designated as 4-[5-(4-methylphenyl)- 3-(trifluoromethyl)-1H-pyrazol-1-yl] benzenesulfonamide and is a diaryl-substituted pyrazole. The empirical formula is C17H14F3N3O2S, and the molecular weight is 381.38; the chemical structure is as follows: Celecoxib capsules for oral administration contain either 50 mg, 100 mg, or 200 mg of celecoxib, together with inactive ingredients including: crospovidone, sodium lauryl sulphate, povidone, magnesium stearate. The capsule shell contains gelatin and titanium dioxide. The capsule imprinting ink for the 50 mg strength contains shellac, ethyl alcohol, isopropyl alcohol, butyl alcohol, propylene glycol, sodium hydroxide, titanium dioxide, povidone and FD&C Red #40 Aluminum Lake. The capsule imprinting ink for the 100 mg strength contains shellac, ethyl alcohol, isopropyl alcohol, butyl alcohol, propylene glycol, strong ammonia solution, and FD&C Blue #2 Aluminum Lake. The capsule imprinting ink for the 200 mg strength contains shellac, ethyl alcohol, isopropyl alcohol, butyl alcohol, propylene glycol, strong ammonia solution, iron oxide yellow, and dimethicone. Capxib - Clinical Pharmacology NONCLINICAL TOXICOLOGY CLINICAL STUDIES HOW SUPPLIED/STORAGE AND HANDLING Celecoxib capsules 50 mg are available for oral administration as hard gelatin capsules with a white opaque body and a white opaque cap. APO C50 is imprinted on each capsule in red ink. They are supplied as follows: Bottles of 30s NDC 60505-3847-3 Bottles of 60s NDC 60505-3847-6 Bottles of 100s NDC 60505-3847-1 Bottles of 1000 NDC 60505-3847-8 Unit Dose Blisters of 100 NDC 60505-3847-0 Celecoxib capsules 100 mg are available for oral administration as hard gelatin capsules with a white opaque body and a white opaque cap. APO C100 is imprinted on each capsule in blue ink. They are supplied as follows: Bottles of 30s NDC 60505-3848-3 Bottles of 100s NDC 60505-3848-1 Bottles of 500s NDC 60505-3848-5 Bottles of 1000 NDC 60505-3848-8 Unit Dose Blisters of 100 NDC 60505-3848-0 Celecoxib capsules 200 mg are available for oral administration as hard gelatin capsules with a white opaque body and a white opaque cap. APO C200 is imprinted on each capsule in yellow ink. They are supplied as follows: Bottles of 30s NDC 60505-3849-3 Bottles of 100s NDC 60505-3849-1 Bottles of 500s NDC 60505-3849-5 Bottles of 1000 NDC 60505-3849-8 Unit Dose Blisters of 100 NDC 60505-3849-0 Patient Counseling Information Patients should be informed of the following information before initiating therapy with celecoxib capsules and periodically during the course of ongoing therapy. MEDICATION GUIDE Medication Guide for Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) What is the most important information I should know about medicines called Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)? NSAIDs can cause serious side effects, including: Increased risk of a heart attack or stroke that can lead to death. This risk may happen early in treatment and may increase: with increasing doses of NSAIDs with longer use of NSAIDs Do not take NSAIDs right before or after a heart surgery called a coronary artery bypass graft (CABG)." Avoid taking NSAIDs after a recent heart attack, unless your healthcare provider tells you to. You may have an increased risk of another heart attack if you take NSAIDs after a recent heart attack. Increased risk of bleeding, ulcers, and tears (perforation) of the esophagus (tube leading from the mouth to the stomach), stomach and intestines: anytime during use without warning symptoms that may cause death The risk of getting an ulcer or bleeding increases with: past history of stomach ulcers, or stomach or intestinal bleeding with use of NSAIDs taking medicines called corticosteroids , anticoagulants , SSRIs , or SNRIs increasing doses of NSAIDs longer use of NSAIDs smoking drinking alcohol older age poor health advanced liver disease bleeding problems NSAIDs should only be used: : exactly as prescribed at the lowest dose possible for your treatment for the shortest time needed What are NSAIDs? NSAIDs are used to treat pain and redness, swelling, and heat (inflammation) from medical conditions such as different types of arthritis, menstrual cramps, and other types of short-term pain. Who should not take NSAIDs? Do not take NSAIDs: if you have had an asthma attack, hives, or other allergic reaction with aspirin or any other NSAIDs. right before or after heart bypass surgery. Before taking NSAIDs, tell your healthcare provider about all of your medical conditions, including if you: have liver or kidney problems have high blood pressure have asthma are pregnant or plan to become pregnant. Talk to your healthcare provider if you are considering taking NSAIDs during pregnancy. You should not take NSAIDs after 29 weeks of pregnancy. are breastfeeding or plan to breast feed. Tell your healthcare provider about all of the medicines you take, including prescription or over-the-counter medicines, vitamins or herbal supplements. NSAIDs and some other medicines can interact with each other and cause serious side effects. Do not start taking any new medicine without talking to your healthcare provider first. What are the possible side effects of NSAIDs? NSAIDs can cause serious side effects, including: See What is the most important information I should know about medicines called Nonsteroidal Anti-inflammatory Drugs (NSAIDs)? new or worse high blood pressure heart failure liver problems including liver failure kidney problems including kidney failure low red blood cells (anemia) life-threatening skin reactions life-threatening allergic reactions Other side effects of NSAIDs include: stomach pain, constipation, diarrhea, gas, heartburn, nausea, vomiting, and dizziness. Get emergency help right away if you get any of the following symptoms: shortness of breath or trouble breathing chest pain weakness in one part or side of your body slurred speech swelling of the face or throat Stop taking your NSAID and call your healthcare provider right away if you get any of the following symptoms: nausea more tired or weaker than usual diarrhea itching your skin or eyes look yellow indigestion or stomach pain flu-like symptoms vomit blood there is blood in your bowel movement or it is black and sticky like tar unusual weight gain skin rash or blisters with fever swelling of the arms, legs, hands and feet If you take too much of your NSAID, call your healthcare provider or get medical help right away. These are not all the possible side effects of NSAIDs. For more information, ask your healthcare provider or pharmacist about NSAIDs. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. Other information about NSAIDs Aspirin is an NSAID but it does not increase the chance of a heart attack. Aspirin can cause bleeding in the brain, stomach, and intestines. Aspirin can also cause ulcers in the stomach and intestines. Some NSAIDs are sold in lower doses without a prescription (over-the-counter). Talk to your healthcare provider before using over-the-counter NSAIDs for more than 10 days. General information about the safe and effective use of NSAIDs Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use NSAIDs for a condition for which it was not prescribed. Do not give NSAIDs to other people, even if they have the same symptoms that you have. It may harm them. If you would like more information about NSAIDs, talk with your healthcare provider. You can ask your pharmacist or healthcare provider for information about NSAIDs that is written for health professionals. This Medication Guide has been approved by the U.S. Food and Drug Administration. APOTEX INC. CELECOXIB CAPSULES 50 mg, 100 mg and 200 mg Manufactured by: Manufactured for: Apotex Inc Apotex Corp. Toronto, Ontario Weston, Florida Canada, M9L 1T9USA 33326 Revised: July 2015 TRANS-D PATCH ACTIVE INGREDIENTS Menthol 5.00%, Capsaicin 0.0375% USES For the temporary relief of minor aches and pains of the muscles and joints associated with simple backache, arthritis, sprains, brulses and strains. Warnings For external use only. Use only as directed. Avoid contact with eyes and mucous membranes. Do not cover with bandage. Do not use on wounds or damaged skin. Do not use in combination with any other external analgesic products. Avoid Contact with eyes and mucous membranes. Do not use on irritated or broken skin, or use in combination with any bandage, wrap, stocking or similar device or garment. DIRECTIONS OTHER INGREDIENTS WATER, GLYCERINE, SODIUM POLYACRYLATE, POLYSORBATE 80, ALOE BARBADESIS LEAF (ALOE VERA GEL) JUICE, EDTA DISODIUM SALT, DIAZOLIDINYL UREA, METHYLPARABEN, LODOPROYNYL BUTYLCABAMATE, PROPYLPARABEN. CELECOXIB CAPSULES 200MG 15 COUNT TRANS-D PATCH 15 COUNT PACKAGE LABEL NDC # 69677-040-02 Kit Contains: 15 Celecoxib 200mg Oral Capsules 15 Capsaicin 0.0375% Menthol 5% Patches PACKAGE LABEL NDC # 69677-040-03 Kit Contains: 15 Celecoxib 200mg Oral Capsules 30 Capsaicin 0.0375% Menthol 5% Patches Capxib celecoxib, menthol, capsaicin kit Product Information Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:69677-040 Packaging # Item Code Package Description 1 NDC:69677-040-03 1 KIT in 1 BOX 2 NDC:69677-040-02 1 KIT in 1 BOX Quantity of Parts Part # Package Quantity Total Product Quantity Part 1 1 BOTTLE 15 Part 2 1 BOX 15 Part 1 of 2 CELECOXIB celecoxib capsule Product Information Route of Administration ORAL DEA Schedule Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength CELECOXIB (CELECOXIB) CELECOXIB 200 mg Inactive Ingredients Ingredient Name Strength SHELLAC ALCOHOL DIMETHICONE TITANIUM DIOXIDE ISOPROPYL ALCOHOL BUTYL ALCOHOL PROPYLENE GLYCOL GELATIN SODIUM LAURYL SULFATE AMMONIA FERRIC OXIDE YELLOW POVIDONES CROSPOVIDONE MAGNESIUM STEARATE Product Characteristics Color white Score no score Shape CAPSULE Size 18mm Flavor Imprint Code APO;C200 Contains Packaging # Item Code Package Description 1 15 CAPSULE in 1 BOTTLE Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date ANDA ANDA204197 06/03/2015 Part 2 of 2 TRANS-D menthol/capsaicin patch Product Information Route of Administration TOPICAL DEA Schedule Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength MENTHOL (MENTHOL) MENTHOL 50 mg CAPSAICIN (CAPSAICIN) CAPSAICIN 0.0375 mg Inactive Ingredients Ingredient Name Strength DIAZOLIDINYL UREA PROPYLPARABEN WATER GLYCERIN EDETATE DISODIUM METHYLPARABEN Packaging # Item Code Package Description 1 15 PATCH in 1 BOX Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date OTC monograph not final part348 03/19/2015 Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date unapproved drug other 04/08/2016 Labeler - MAS Management Group (079363782) Revised: 09/2017 MAS Management Group} FEATURED: CAR-T Cell Therapy Overview Mechanism of Action KTE-C19 Studies KTE-C19 Cancer Targets Adverse Events Manufacturing Recently Approved Lonhala Magnair Lonhala Magnair (glycopyrrolate) is a long-acting muscarinic antagonist (LAMA) bronchodilator for... Ozempic Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) analog administered once-weekly for the... Ogivri Ogivri (trastuzumab-dkst) is a HER2 / neu receptor antagonist biosimilar to Herceptin indicated for... Sublocade Sublocade (buprenorphine) is a once-monthly injectable partial opioid agonist formulation for the... More} } instance


soliciting for Capxib for boosting


EmoticonEmoticon